Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Prostate Cancer Metastatic × olaparib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Ovarian Neoplasms 73 Breast Neoplasms 54 Prostatic Neoplasms 29 Triple Negative Breast Neoplasms 22 Fallopian Tube Neoplasms 21 Neoplasms 20 Pancreatic Neoplasms 16 Endometrial Neoplasms 16 Neoplasm Metastasis 15 Small Cell Lung Carcinoma 13 Carcinoma, Ovarian Epithelial 9 Stomach Neoplasms 8 Squamous Cell Carcinoma of Head and Neck 8 Sarcoma 8 Carcinoma, Non-Small-Cell Lung 8 Recurrence 7 Glioma 7 Lung Neoplasms 6 Fanconi Anemia, Complementation Group D1 6 Colorectal Neoplasms 6 Lymphoma, Non-Hodgkin 5 Glioblastoma 5 Cholangiocarcinoma 5 Urinary Bladder Neoplasms 4 Solid Tumors 4 Parkinson Disease 4, Autosomal Dominant Lewy Body 4 Neuroendocrine Tumors 4 Metastatic Castration-resistant Prostate Cancer 4 Advanced Solid Tumors 4 Advanced Breast Cancer 4

Interventions

enzalutamide 7 Prednisone 7 cabazitaxel 6 Radiosurgery 5 Docetaxel 5 Androgen Antagonists 4 Abiraterone Acetate 4 XRP6258 2 talazoparib 1 sipuleucel-T 1 rucaparib 1 pembrolizumab 1 olaparib 1 gallium 68 PSMA-11 1 fludrocortisone acetate 1 darolutamide 1 apalutamide 1 Zuclomiphene 1 Standard of Care 1 Radiotherapy, Image-Guided 1 Radiotherapy 1 Prednisolone 1 Positron Emission Tomography Computed Tomography 1 Pluvicto 1 Lutetium-177 1 Lutetium 1 Lenograstim 1 LY3023414 1 Injections 1 Hydrocortisone 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03434158 2022-11-03

IMANOL

Spanish Oncology Genito-Urinary Group

Phase 2 Completed

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡